Armelle Phalipon

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study.

Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study.

Journal: The Lancet. Infectious diseases

Published: April 28, 2026

Controlled human infection trials: Legitimacy and conditions of implementation in France.

Controlled human infection trials: Legitimacy and conditions of implementation in France.

Journal: Therapie

Published: November 27, 2023

Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate.

Further characterization of Shigella-specific (memory) B cells induced in healthy volunteer recipients of SF2a-TT15, a Shigella flexneri 2a synthetic glycan-based vaccine candidate.

Journal: Frontiers in immunology

Published: September 09, 2023

The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.

The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.

Journal: Vaccine

Published: April 25, 2023

A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.

A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults.

Journal: NPJ vaccines

Published: October 11, 2022

Toward a Multivalent Synthetic Oligosaccharide-Based Conjugate Vaccine against Shigella: State-of-the-Art for a Monovalent Prototype and Challenges.

Toward a Multivalent Synthetic Oligosaccharide-Based Conjugate Vaccine against Shigella: State-of-the-Art for a Monovalent Prototype and Challenges.

Journal: Vaccines

Published: January 11, 2022

The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella.

The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella.

Journal: ACS central science

Published: December 01, 2021

2019 - A year of celebrations.

2019 - A year of celebrations.

Journal: Cellular microbiology

Published: October 28, 2019

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.

Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.

Journal: The Lancet. Infectious diseases

Published: September 25, 2019

Shigella impairs human T lymphocyte responsiveness by hijacking actin cytoskeleton dynamics and T cell receptor vesicular trafficking.

Shigella impairs human T lymphocyte responsiveness by hijacking actin cytoskeleton dynamics and T cell receptor vesicular trafficking.

Journal: Cellular microbiology

Published: August 07, 2019

Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses.

Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses.

Journal: Human vaccines & immunotherapeutics

Published: April 10, 2019

Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.

Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.

Journal: Vaccine

Published: December 07, 2018

Showing 1-12 of 26

Last Updated: 09/26/2026